Summit Therapeutics (NASDAQ:SMMT) will release its earnings data before the market opens on Wednesday, December 6th. Analysts expect Summit Therapeutics to post earnings of ($0.73) per share for the quarter.

Shares of Summit Therapeutics (NASDAQ:SMMT) traded up $0.34 during mid-day trading on Tuesday, reaching $12.02. The company’s stock had a trading volume of 9,100 shares, compared to its average volume of 22,156. Summit Therapeutics has a 12 month low of $7.95 and a 12 month high of $16.86.

A number of research analysts have recently commented on SMMT shares. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Summit Therapeutics in a report on Friday. Zacks Investment Research raised Summit Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. Canaccord Genuity reissued a “buy” rating on shares of Summit Therapeutics in a report on Monday, October 16th. Oppenheimer reissued a “buy” rating and set a $24.00 price objective on shares of Summit Therapeutics in a report on Monday, October 16th. Finally, ValuEngine lowered Summit Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Summit Therapeutics currently has an average rating of “Hold” and an average target price of $20.25.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/05/summit-therapeutics-smmt-set-to-announce-earnings-on-wednesday.html.

Summit Therapeutics Company Profile

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.